Zacks Investment Research
22 Sept 2026, 20:35 UTC · 1h ago
Verdict
Headline takes no side. We score RHHBY +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Roche's enicepatide reduced HbA1c by 2.65% and mean body weight by 15.5% at the 24 mg dose in a Phase II study.
Newreported September 22, 2026
More positive than 92% of claims this week
In patients with HbA1c >8.5%, enicepatide 24 mg achieved a significant HbA1c reduction of 4.13% at 48 weeks.
New
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatHigher efficacy in poorly controlled patients could expand the addressable patient population and peak sales estimates.
More positive than 76% of claims this week
The drug demonstrated high tolerability with a 2.0% discontinuation rate due to adverse events in treatment groups.
Newreported September 22, 2026
More positive than 62% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
Reported encouraging top-line results from a mid-stage study of its obesity and diabetes drug enicepatide.
More positive than 76% of relationship scores this week
[mutual] Eli Lilly and Novo Nordisk are identified as established therapies in the crowded incretin market.
More positive than 76% of relationship scores this week
[mutual] Roche is seeking to compete with Eli Lilly in the incretin market for obesity and type 2 diabetes.
More positive than 76% of relationship scores this week
[mutual] Roche is seeking to compete with Novo Nordisk in the incretin market for obesity and type 2 diabetes.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
10h ago
—
RHHBY hasn't traded since this ran. Last close $55.63 (Sep 22); the reaction starts at the next open.
RHHBY chart →